Novartis Kisqali(R) prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2- metastatic breast cancer compared to chemotherapy

(marketscreener.com) Dow Jones Newswires December 06, 2022 13:30 ET https://www.marketscreener.com/quote/stock/NOVARTIS-AG-9364983/news/Novartis-Kisqali-R-prolonged-PFS-benefit-for-pre-and-perimenopausal-patients-with-aggressive-HR-H-42489163/?utm_medium=RSS&utm_content=20221206